Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link
Key Market Insights
- More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development efforts
- The pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routes
- Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domain
- Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development
- A number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development efforts
- Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACs
- Foreseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014
- The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companies
- Short term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needs
- As multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions
For more information please visit:
https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3.1. Context and Background
3.2. Concept of Protein Homeostasis
3.3. Discovery of the Ubiquitin Proteasome System
3.3.1. Ubiquitin: Structure and Function
3.3.2. Fundamentals of the UPS
3.3.3. Components of the UPS
3.4. Key Steps Involved in the UPS
3.4.1. Ubiquitination: The First Step
3.4.2. Proteasomal Degradation: The Second Step
3.5. Therapeutic Applications of the UPS
3.6. Advantages and Challenges Associated with Ubiquitin Enzyme Inhibitors
3.7. Targeted Protein Degradation: Enhancing Ubiquitination to Degrade Undruggable Targets
3.7.1. Brief History of Targeted Protein Degradation
3.8. Types of Protein Degraders
3.8.1. Selective Hormone Receptor Degraders (SHRDs)
3.8.2. Immumodulatory Imide Drugs (IMiDs)
3.8.3. PROTACs
3.8.4. Other Chimeras (ENDTACs, LYTACs and PHOTACs)
3.8.4.1. Endosome Targeting Chimeras (ENDTACs)
3.8.4.2. Lysozyme targeting chimeras (LYTACs)
3.8.5. Specific and Nongenetic Inhibitor-of-Apoptosis Proteins (IAP)-dependent Protein Erasers (SNIPERS)
3.8.6. Hydrophobic Tag
3.8.7. Molecular Glues
3.8.8. DUB Inhibitors
3.9. Growth Drivers and Roadblocks
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Enzyme
4.2.6. Analysis by Type of Target Protein
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Location of Headquarters
4.4.3. Analysis by Size of Company
4.4.4. Analysis by Type of Protein Degrader
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Targeted Protein Degradation-based Drug Portfolio
5.2.1.2.1. Product Description: Elacestrant
5.2.1.3. Recent Developments and Future Outlook
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
5.2.2.3.1. Avadomide (CC-122)
5.2.2.3.2. Iberdomide (CC-220)
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
5.2.3.3.1. Product Description: SAR439859
5.2.3.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical / Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Clinical Trials
6.3.3. Geographical Analysis by Enrolled Patient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor / Collaborator
6.3.8. Most Active Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysis by Type of Organization
7.3.2. Analysis by Designation
7.3.3. Geographical Distribution
7.3.4. Analysis by Therapeutic Focus
7.3.5. Analysis by Phase of Development and Type of Degrader
7.4. Prominent Key Opinion Leaders
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
7.6. Most Active Key Opinion Leaders
7.6.1. KOL Profile (Hagop Youssoufian)
7.6.2. KOL Profile (Patricia LoRusso)
7.6.3. KOL Profile (Johann De Bono)
7.6.4. KOL Profile (John N Nemunaitis)
7.6.5. KOL Profile (Robert Morgan)
7.6.6. KOL Profile (Edward O’Mara)
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Targeted Protein Degradation-Based Therapeutics and Technologies: Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Study Objective
8.3.3. Emerging Focus Areas
8.3.4. Analysis by Type of Protein Degrader
8.3.5. Analysis by Target Protein
8.3.6. Analysis by Target Enzyme
8.3.7. Analysis by Target Indication
8.3.8. Analysis by Type of Publisher
8.3.9. Leading Players: Analysis by Number of Publications
8.3.10. Leading Players: Geographical Analysis by Number of Publications
8.3.11. Key Journals: Analysis by Number of Publications
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Protein Degraders
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different Protein Degradation Technology Platforms
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Geographical Analysis by Amount Invested
9.4. Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Protein Degrader
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Different Protein Degradation Technology
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
10.3.7.2. Intercontinental and Intracontinental Agreements
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030
11.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market by Upfront Payments, 2020-2030
11.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market by Milestone Payments, 2020-2030
11.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
11.3.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030
11.3.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030
11.3.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs / SERDs, 2020-2030
11.3.3.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
11.3.3.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Protein Degraders, 2020-2030
11.3.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
11.3.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-2030
11.3.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030
11.3.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030
11.3.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
11.3.5.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030
11.3.5.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030
11.3.5.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030
11.3.6. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
11.3.6.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030
11.3.6.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030
11.3.6.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030
13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
71968